Three-Drug attack on dangerous leukemia

This study is testing whether adding a drug called venetoclax to the standard two-drug treatment can improve outcomes for people newly diagnosed with a rare and aggressive blood cancer called acute promyelocytic leukemia (APL), specifically those with very high white blood cell counts. The trial will enroll 28 patients to see if this three-drug combination is safe and helps more patients achieve remission. The goal is to control this dangerous form of leukemia better than current treatments can.